An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study

BACKGROUND: Miridesap depletes circulating serum amyloid P (SAP) and dezamizumab (anti-SAP monoclonal antibody) targets SAP on amyloid deposits, triggering amyloid removal. In a phase 1, first-in-human study (FIHS), progressive amyloid removal was observed in some patients after ≤ 3 cycles of miride...

Descripción completa

Detalles Bibliográficos
Autores principales: Richards, Duncan, Millns, Helen, Cookson, Louise, Lukas, Mary Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271258/
https://www.ncbi.nlm.nih.gov/pubmed/35810311
http://dx.doi.org/10.1186/s13023-022-02405-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271258/
https://www.ncbi.nlm.nih.gov/pubmed/35810311
http://dx.doi.org/10.1186/s13023-022-02405-7

Ejemplares similares